先天性血栓性血小板减少性紫癜患者血浆输注的药代动力学
该研究对6例先天性血栓性血小板减少性紫癜(TTP)患者血浆输注后ADAMTS-13进行药代动力学分析,中位清除率25.41 mL h-1,中位半衰期130小时(范围82.6–189.5小时,即3.4–7.9天)。所有患者血浆输注后7–10天ADAMTS-13恢复至基线水平,输注后中位活性峰值24.05 IU dL-1。模拟提示目标谷浓度10 IU dL-1可行,而50 IU dL-1因所需血浆容量而无法达到。
要点
- 6例先天性TTP患者血浆输注后ADAMTS-13中位半衰期为130小时。
- 所有患者血浆输注后7–10天ADAMTS-13恢复至基线水平。
- 模拟提示目标谷浓度10 IU dL-1可行,50 IU dL-1因血浆容量需求无法达到。
核心结论
- 需进一步研究比较血浆输注与重组ADAMTS-13治疗先天性TTP;血浆输注可能提供更长的ADAMTS-13作用持续时间,但受所需血浆容量限制,而重组治疗可提供更高的ADAMTS-13峰值。
- 作者提出有必要研究ADAMTS-13的个体间清除率以优化治疗,并为预防治疗的剂量和频率提供依据。
研究设计与样本
- 对6例接受既定方案血浆输注的先天性TTP患者进行ADAMTS-13药代动力学分析。
主要发现
- 中位清除率为25.41 mL h-1,中位半衰期为130小时,范围82.6–189.5小时(即3.4–7.9天)。
- 所有患者血浆输注后7–10天ADAMTS-13恢复至基线水平。
- 血浆输注后ADAMTS-13活性中位峰值为24.05 IU dL-1。
- 变异与消除速率相关,而消除速率受体重和代谢影响,但与血管性血友病因子抗原或活性水平无关。
- 利用药代动力学参数模拟基于血浆输注剂量或频率的个体化方案,分别以 hypothetical 最佳血浆ADAMTS-13水平10和50 IU dL-1为目标;结果提示目标谷浓度10 IU dL-1可行,但考虑到所需容量,50 IU dL-1无法达到。
局限性
- 关于最佳剂量和治疗频率的证据稀少,治疗倾向于经验性指导。
- 需进一步研究比较血浆输注与重组ADAMTS-13治疗先天性TTP。
- 作者提出有必要研究ADAMTS-13的个体间清除率以优化治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Essentials Congenital thrombotic thrombocytopenic purpura (TTP) is primarily treated with plasma infusion. We present a pharmacokinetic analysis of ADAMTS-13 in six patients following plasma infusion. A median half-life of 130 h was demonstrated, ranging between 82.6 and 189.5 h. Investigation of interindividual clearance of ADAMTS-13 is necessary to optimize treatment. SUMMARY: Background Congenital thrombotic thrombocytopenic purpura (TTP) is defined by persistent severe deficiency of ADAMTS-13 in the absence of anti-ADAMTS-13 inhibitory antibodies, confirmed by mutational analysis. Replacement of the missing protease prevents disease relapse, primarily using plasma infusion (PI). Objectives, patients and methods There is scant evidence regarding optimal dose and frequency of treatment, which tends to be empirically guided. We present a pharmacokinetic analysis of ADAMTS-13 in six patients with congenital TTP on established regimes following PI. Results We found a median clearance of 25.41 mL h-1 and half-life of 130 h, ranging between 82.6 and 189.5 h (3.4-7.9 days, respectively). All patients reached baseline ADAMTS-13 level within 7-10 days post-plasma. Median ADAMTS-13 activity peak post-PI was 24.05 IU dL-1 . Variation was related to elimination rate, which, in turn, was affected by weight and metabolism, but not to von Willebrand factor antigen or activity levels. Using the pharmacokinetic parameters, we simulated individualized protocols based on PI dose or frequency to target hypothetical optimal plasma levels of ADAMTS-13 of 10 and 50 IU dL-1 , respectively. Results suggest a target trough ADAMTS-13 of 10 IU dL-1 is feasible but 50 IU dL-1 would not be achievable taking into account volume required. Conclusions Further work is needed to compare treatment of congenital TTP with PI vs. recombinant ADAMTS-13. PI may provide longer duration of ADAMTS-13 effect, but is limited by plasma volume required, whereas recombinant therapy can provide a higher ADAMTS-13 peak. We propose that investigation of interindividual clearance of ADAMTS-13 is necessary to optimize treatment and provide the rationale for dose and frequency of prophylaxis.
引用
- Taylor A, Vendramin C, Oosterholt S, et al. Pharmacokinetics of plasma infusion in congenital thrombotic thrombocytopenic purpura. J Thromb Haemost. 2018. PMID: 30475428. doi:10.1111/jth.14345
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。